Market capitalization | $194.02m |
Enterprise Value | $204.12m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.18 |
P/S ratio (TTM) P/S ratio | 3.02 |
P/B ratio (TTM) P/B ratio | 45.75 |
Revenue growth (TTM) Revenue growth | 28.14% |
Revenue (TTM) Revenue | $64.25m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
9 Analysts have issued a AVITA Therapeutics forecast:
9 Analysts have issued a AVITA Therapeutics forecast:
Dec '24 |
+/-
%
|
||
Revenue | 64 64 |
28%
28%
|
|
Gross Profit | 55 55 |
30%
30%
|
|
EBITDA | -55 -55 |
54%
54%
|
EBIT (Operating Income) EBIT | -57 -57 |
54%
54%
|
Net Profit | -62 -62 |
75%
75%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. Its product, RECELL system, is a device that enables healthcare professionals to produce a suspension of spray-on skin cells using a small sample of the patient's own skin for the treatment of acute thermal burns. The company was founded in December 1992 and is headquartered in Valencia, CA.
Head office | United States |
CEO | James Corbett |
Employees | 260 |
Founded | 1992 |
Website | www.avitamedical.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.